anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this study is to assess knowledge, beliefs and attitudes of parents to young girls aged 9 to 14 years about HPV vaccines within some rural communities in the North West Region of Cameroon served by three hospitals in that area. Snowball sampling technique will be used. Parents of girls aged 9-14years will be included if the daughters have or have not received the HPV vaccine. Exclusion criteria include parents who are health care workers in any health institution, unwilling to provide consent, or inability to converse in English or pidgeon English. In-depth one-on-one interviews will take place using an interview guide. Interviews will be in English or pidgeon English. They will be taped and transcribed. Data will be entered into ATLAS Ti. Data analysis will be done concurrently with interviews using thematic analysis.Interviews will continue until theme saturation is reached (We anticipate a total 40 interviews).
1. Technical Result Increase in assortment of medicinal and diagnostic preparations against inflammatory and immune related diseases.          2. Essence A method of controlling the amount of sialic acid available in oligosaccaride side chain of chimerical glycoprotein (which consists of tumor necrosis factor and antibody) produced by mammalian cell culture, the preparations containing the mentioned chimerical glycoprotein and their use are provided.          3. Field of Application Medicine, therapy, diagnosis.
Soldiers deployed to Iraq and Afghanistan have a higher prevalence of respiratory symptoms than nondeployed military personnel and some have been shown to have a constellation of findings on lung biopsy termed post-deployment respiratory syndrome (PDRS). Since many of the subjects in this cohort reported exposure to sulfur dioxide (SO2), we developed a model of repetitive exposure to SO2 in mice that phenocopies many aspects of PDRS, including adaptive immune activation, airway wall remodeling, and pulmonary vascular (PV) disease. Although abnormalities in small airways were not sufficient to alter lung mechanics, PV remodeling resulted in the development of pulmonary hypertension and reduced exercise tolerance in SO2-exposed mice. SO2 exposure led to increased formation of isolevuglandins (isoLGs) adducts and superoxide dismutase 2 (SOD2) acetylation in endothelial cells, which were attenuated by treatment with the isoLG scavenger 2-hydroxybenzylamine acetate (2-HOBA). In addition, 2-HOBA treatment or Siruin-3 overexpression in a transgenic mouse model prevented vascular remodeling following SO2 exposure. In summary, our results indicate that repetitive SO2 exposure recapitulates many aspects of PDRS and that oxidative stress appears to mediate PV remodeling in this model. Together, these findings provide new insights regarding the critical mechanisms underlying PDRS.NEW & NOTEWORTHY We developed a mice model of "post-deployment respiratory syndrome" (PDRS), a condition in Veterans with unexplained exertional dyspnea. Our model successfully recapitulates many of the pathological and physiological features of the syndrome, revealing involvement of the ROS-isoLGs-Sirt3-SOD2 pathway in pulmonary vasculature pathology. Our study provides additional knowledge about effects and long-term consequences of sulfur dioxide exposure on the respiratory system, serving as a valuable tool for future PDRS research.
2,4-Diamino 6-piperidino-pyrimidine 3-oxide is made by (a) reaction of 6-chloro 2,4-diamino pyrimidine with a percarboxylic acid, e.g. 3-chloro perbenzoic acid or peracetic acid in approx. equimolar amts. in an inert organic solvent, e.g. ethanol and (b) removal of the solvent and reaction with piperidine in molar excess for 6-10 times, at reflux temp. The required prod. is pptd. by cooling and purified by washing and extn.
Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
All injections were performed by him under the guidance of a Clarius portable USG device (L7 HD Linear Ultrasound Scanner). A total of 10 ml of a mixture of 1 ml of 40 mg triamcinolone acetonide (Kenakort-A ampoule) and 9 ml of 0.5% bupivacaine hydrochloride (Marcaine) was used in each injection.
BACKGROUND: In 2015, the Spanish National Transplant Organization developed a prioritization system (Program for Access to Transplantation for Highly Sensitized Patients [PATHI]) to increase transplant options for patients with calculated panel-reactive antibodies (cPRAs) ≥98%, based on virtual crossmatch. We describe the experience with the implementation of PATHI and assess its efficacy.
METHODS: PATHI registry was used to collect characteristics of donors and patients between June 15, 2015, and March 1, 2018. One-year graft and patient survival and acute rejection were also measured. A Cox model was used to identify factors related to patient death and graft loss and logistical regression for those associated with rejection.
RESULTS: One thousand eighty-nine patients were included, and 272 (25%) were transplanted. Transplant rate by cPRA was 54.9%, 40.5%, and 12.8% in patients with cPRA98%, cPRA99%, and cPRA100%, respectively. One-year patient survival was 92.5%. Recipient age ≥60, time under dialysis >7 y, and delayed graft function were mortality risk factors. One-year graft survival was 88.7%. The factor related to graft loss was delayed graft function. The rejection rate was 22%. Factors related to rejection were sex, older recipients, and posttransplant donor-specific antibodies.
CONCLUSIONS: A prioritization approach increases transplant options for highly sensitized patients with appropriate short-term postransplant outcomes. Along with other programs, PATHI may inspire other countries to adopt strategies to meet transplant needs of these patients.
In a method of neurological assessment, multichannel electromyography (EMG) data are acquired for an anatomical region. A pairwise EMG channel‑EMG channel similarity matrix is generated from the acquired multichannel EMG data. Network analysis is performed on the similarity matrix to generate a network representing the similarity matrix. One or more metrics of the network are computed. One or more biomarkers are determined for the anatomical region based on the one or more metrics. In another method, EMG data are acquired using an electrode array contacting skin of a target anatomy, the EMG data are processed to produce reduced-dimensionality data; and time-invariant muscle synergies and corresponding time-varying activation functions are determined in the reduced-dimensionality data.
PURPOSE:To prepare a dentifrice composition having improved residual activity of dextranase, feeling to the mouth, and stability, by compounding a dextranase-containing dentifrice composition with specific amounts of the higher alcohol sulfuric acid ester and an N-(long-chain acyl)amino acid, etc. CONSTITUTION:A dentifrice composition containing dextranase is compounded with (A) a higher alcohol sulfuric acid ester or its salt (esp. sodium laurylsulfate) and (B) an N-(long-chain acyl)amino acid or its salt (esp. lauroylsarcosine sodium salt). The weight ratio of A:B is 1:2-2:1. The composition is pref. further compounded with 20-150wt%, based on A+B, of a nonionic surface active agent. The amount of the B component is pref. 0.2-0.5 wt% of the whole dentifrice composition. The composition has low deactivation of dextranase, and excellent feeling to the mouth, e.g. foamability, etc., stability of the preparation, and safety to the oral mucosa.
The present invention relates to a skin-whitening composition containing a fermented Stachys japonica Miq. extract fermented by using Hericium erinaceus (Bull.) Pers. mycelium as an active ingredient. More specifically, the hot water extract of the fermented Stachys japonica Miq. fermented by using the Hericium erinaceus (Bull.) Pers. Mycelium has almost no cytotoxicity in comparison with hot water extracts of Stachys japonica Miq, and remarkably inhibits activities of tyrosinase, thereby being safe and useful for drugs and health functional foods for preventing, ameliorating, or treating hyperpigmentation by melanin or cosmetic products for skin whitening.
Application to mucous membranes should be avoided due to the possibility of local inflammation and ulceration. Additionally, cases of miscarriage and a birth defect (ventricular septal defect) have been reported when fluorouracil was applied to mucous membrane areas during pregnancy.

Occlusion of the skin with resultant hydration has been shown to increase percutaneous penetration of several topical preparations. If any occlusive dressing is used in treatment of basal cell carcinoma, there may be an increase in the severity of inflammatory reactions in the adjacent normal skin. A porous gauze dressing may be applied for cosmetic reasons without increase in reaction.

Exposure to ultraviolet rays should be minimized during and immediately following treatment with fluorouracil because the intensity of the reaction may be increased.

Patients should discontinue therapy with fluorouracil if symptoms of DPD enzyme deficiency develop (see CONTRAINDICATIONS).

Rarely, life-threatening toxicities such as stomatitis, diarrhea, neutropenia, and neurotoxicity have been reported with intravenous administration of fluorouracil in patients with DPD enzyme deficiency. One case of life-threatening systemic toxicity has been reported with the topical use of fluorouracil in a patient with DPD enzyme deficiency. Symptoms included severe abdominal pain, bloody diarrhea, vomiting, fever, and chills. Physical examination revealed stomatitis, erythematous skin rash, neutropenia, thrombocytopenia, inflammation of the esophagus, stomach, and small bowel. Although this case was observed with 5% fluorouracil cream, it is unknown whether patients with profound DPD enzyme deficiency would develop systemic toxicity with lower concentrations of topically applied fluorouracil.
PURPOSE: The aim of this study was to investigate whether luteoloside, a flavonoid, could protect human dental pulp cells (HDPCs) against inflammation and oxidative stress induced by methylglyoxal (MGO), one of the advanced glycated end products (AGE) substances.
METHODS: HDPCs were stimulated with MGO and treated with luteoloside. MTT assay was used to determine cell viability. Protein expression was measured via western blotting. Reactive oxygen species (ROS) were measured with a Muse Cell Analyzer. Alkaline phosphatase activity (ALP) and Alizarin red staining were used for mineralization assay.
RESULTS: Luteoloside down-regulated the expression of inflammatory molecules such as ICAM-1, VCAM-1, TNF-α, IL-1β, MMP-2, MMP-9, and COX-2 in MGO-induced HDPCs without showing any cytotoxicity. It attenuated ROS formation and enhanced osteogenic differentiation such as ALP activity and Alizarin red staining in MGO-induced HDPCs. Overall, luteoloside showed protective actions against inflammation and oxidative stress in HDPCs induced by MGO through its anti-inflammatory, anti-oxidative, and osteogenic activities by down-regulating p-JNK in the MAPK pathway.
CONCLUSION: These results suggest that luteoloside might be a potential adjunctive therapeutic agent for treating pulpal pathological conditions in patients with diabetes mellitus.
FIELD: medicine. ^ SUBSTANCE: there are described polypeptides eliciting an immune response on H.influenzae. There is offered an antibody selectively binding specified polypeptides. The invention also concerns an immunogenic composition containing the described polypeptides. ^ EFFECT: invention can be used in medicine for treating or preventing a disease or an infection caused by Hinfluenzae, such as otitis media. ^ 9 cl, 3 tbl
Purposes: Dilatation of cystic duct is very rare and had been classified as Todani type VI choledochal cyst. Choledochal cyst combined with dilatation of cystic duct is difficult to diagnose preoperatively. The purpose of this study is to report the rare variants and discuss the significance and laparoscopic management strategy in children. Methods: The subjects for this study were 10 consecutive patients with type VI choledochal cyst who had laparoscopic procedures at our institute between January 2009 and January 2023. Laparoscopic cholecystectomy, excision of the dilated cystic duct, and choledochal cyst were carried out, and the continuity of the biliary duct was re-established through a Roux-en-Y hepaticojejunostomy. Results: Cystic duct combined with the common bile duct dilatation was revealed in all the patients intraoperatively. Laparoscopic procedures were completed with no conversions. The postoperative recovery was uneventful. The mean follow-up duration was 27 ± 12.7 months (range 5-36 months) with no postoperative complications encountered. Conclusions: The rare entity of type VI choledochal cyst should be recognized as a distinct type of choledochal cyst and need to be given enough attention clinically. The laparoscopic procedure is a feasible option for experienced surgeons.
A measuring device 20 acquires biometric information relating to a user, and transmits the same to a terminal device 30-1. The terminal device transmits the biometric information to a server 40. The server 40 uses the biometric information relating to the user to calculate physical fitness and mental fitness. Further, the server 40 generates activity support information for the user on the basis of the calculated physical fitness and mental fitness, and transmits the same to the terminal device 30-1. The terminal device 30-1 uses an image or sound to notify the user of the activity support information provided from the server 40. The user is therefore able to determine what kind of activity can be performed for how long, with his or her remaining physical strength, and is able to perform an activity corresponding to his or her remaining physical strength.
There is no mouse model of patellar tendinopathy. This study aimed to establish a mouse inflammatory and degenerative patellar tendon injury model, which will facilitate research on patellar tendinopathy using advanced molecular tools including transgenic models. Collagenase at different doses (low dose (LD), medium dose (MD), high dose (HD)) or saline was injected over the mouse patellar tendon. At weeks 1, 2, 4, and 8 post-injection, the tendons were harvested for histology and further examined by micro-computed tomography (microCT) imaging at week 8. The optimal dose group and the saline group were further evaluated by immunohistochemical staining, gait pattern, and biomechanical properties. The histopathological score increased dose-dependently post-collagenase injection. Ectopic mineralization was observed and increased with collagenase dose. The LD group was selected for further analysis. The expression of IL-10, TNF-α, and MMP-1 significantly increased post-injection. The changes of limb idleness index (ΔLII) compared to preinjury state were significantly higher, while the ultimate load, stiffness, ultimate stress, and maximum Young's modulus were significantly lower in the LD group compared to the saline group. A mouse inflammatory degenerative model of patellar tendon injury resembling tendinopathy was established as indicated by the dose-dependent increase in tendon histopathology, ectopic calcification, decrease in biomechanical properties, and pain-associated gait changes.
Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
An effervescent protein tablet for human consumption comprises (a) protein, (b) an acid, and (c) a base. The tablet is soluble in an aqueous solution and optionally contains (d) a disintegrant. The protein preferably comprises of a plant protein. Preferably the tablet comprises of pea protein and rice protein in a w/w ratio of at least 0.1:1, preferably 0.5:1 to 5:1. The acid is preferably citric acid and the base is preferably sodium bicarbonate. The disintegrant is preferably microcrystalline cellulose or carboxymethyl cellulose. The tablet preferably weighs at least 3g. The protein is preferably present at a concentration of at least 10% w/w. A method of manufacturing an effervescent protein tablet for human consumption comprising combining the ingredients (a), (b) and (c) and optionally (d). The combined ingredients are preferably wetted, moulded and dried to form the tablet. The effervescent tablet may be contacted with water to form an aqueous formulation. The tablet or aqueous formulation formed therefrom may be suitable for use in medicine, muscle repair and/or in promoting anabolic metabolism.
Noncompliance in taking medication is very common among people with schizophrenia, and is a frequent cause of relapse of symptoms. A long-acting injectable formulation that ensures the slow but steady release of risperidone over a period of several weeks would eliminate the need to take medication on a daily basis, and improve compliance. This is an open-label, international, multicenter study in patients with schizophrenia or schizoaffective disorder who either completed study RIS-INT-57 or RIS-INT-61 or who dropped out of RIS-INT-61 after the completion of 3 injection cycles. Patients have to begin this study within 7 days of the final endpoint visit in the RIS-INT-57 or RIS-INT-61 studies. The endpoint visit of RIS-INT-57 and RIS-INT-61 serves as the first visit (Visit 1) of RIS-INT-63, and is considered the baseline of this extension study. Patients who have completed RIS-INT-57 will continue to receive the same dose of long-acting injectable risperidone (25, 50 or 75 mg) as they received during the last 3 months of that study. Patients who have completed or dropped out of RIS-INT-61 will continue to receive the same or equivalent dose of long-acting injectable risperidone as they had received during that study. The blind will not be broken for patients from the RIS-INT-61 study, therefore they will continue to receive double-blind oral medication for the first 3 weeks of this extension study. The total study duration is planned to be at least 1 year. The study hypothesis is that treatment with the long-acting injectable formulation of risperidone every 2 weeks for at least 1 year will be safe and well tolerated, as assessed by adverse event reporting, the extrapyramidal symptom rating scale, laboratory tests, vital signs measurements, physical examinations, body weight measurements, electrocardiograms, and injection site evaluations. Patients will receive injections of risperidone depot in microspheres (25, 50 or 75 mg) in their muscle at 2-weekly intervals for at least 1 year.
A method and system of administering a dissociative unconscious type of anesthesia are disclosed. The method and system are designed for use in office surgical units and outpatient facilities. Administration by a nurse or a physician without anesthesia training can be done with minimum danger to the patient and minimum recovery time. The method and system utilizes the intravenous titration method of administration of a combination of drugs by which the patient is placed in a dissociative, unconscious state and maintained in this state until completion of the procedure, at which time the effect of the drugs is reversed by other drugs as desired. The intravenous anesthesia is supported by infiltration of a local anesthetic, such as Xylocaine. The combination of drugs include the basal hypnotic diazepam (Valium), a dissociated unconsciousness and general analgesia phencyclidine (Ketamine) and the narcotic analgesic Nisentil. The effects of the anesthetic can be reversed by the person administering the anesthesia as soon as their desired purpose has been accomplished.
PROBLEM TO BE SOLVED: To provide a low-cost high quality gelatin to be used for the production of a silver halide emulsion by using a recombination DNA technique. SOLUTION: This silver halide emulsion and the preparation of the AgX emulsion have the following features. The emulsion is a planer silver halide emulsion in which planer particles possess >75% of the projected area of the whole particles. The emulsion contains silver halide particles which are produced as nuclei in the presence of a nuclear forming peptizer and grown in the presence of a growing peptizer. The peptizer is a substantially pure collagen material prepared by genetic engineering, and the peptizer has an amino acid sequence having more than four different amino acids.  By the producing method of the recombinant collagen polypeptide, the expression of the nucleic acid sequence which codes collagen polypeptide is obtd. by microorganisms to a degree over 0.95 g/l, the recombinant collagen has no helical structure, and the expression is obtd. in microorganisms except for Escherichia coli or saccharomyces cerevisiae.
PURPOSE: A composition containing an extract of ground water containing inorganic components and metal ions in large quantities is provided. It exhibits excellent activity on facilitating bowl movement and promoting the secretion of intestinal mucus and thus can be used as a medicine and heath supplementary food for the prevention and treatment of constipation. CONSTITUTION: The composition for the prevention and treatment of constipation contains concentrated powder of a ground water extract. The pharmaceutical composition for the prevention and treatment of constipation contains 0.1 to 80% by weight of concentrated powder of the ground water extract. The ground water extract is obtained by extracting ground water drawn from a ground water zone with a depth of 700 to 1,000m below a sea level of a hot spring area located in Kyunggi province of Korea. The concentrated powder is untreated or desalination-treated. The effective dose amount of the composition is 0.01 to 10g per kg body weight.